Table 1.
Study characteristics describing details on COVID-19
| Study | Country | Sample size total study (n) = 29 | Mortality (events; event rate (%) (95% CI)*; weight (%)#) total study (n) = 21 | Mechanical ventilation (events; event rate (%) (95% CI)*; weight (%)#) total study (n) = 17 |
|---|---|---|---|---|
| Huang et al., Jan 2020 | China | 41 | 6; 14.6 (6.7–29); 4.9 | 4; 9.8 (3.7–23.3); 4.99 |
| Guan et al., Feb 2020 | China | 1099 | 15; 1.4 (0.8–2.3); 5.87 | 67; 6.1 (4.8–7.7); 7.54 |
| Zhao et al., Mar 2020 | China | 19 | NA | 0; 2.5 (0.2–29.8); 1.51 |
| Young et al., Mar 2020 | Singapore | 18 | NA | 1; 5.6 (0.8–30.7); 2.48 |
| Wang et al., Feb 2020 | China | 138 | 6; 4.3 (2–9.3); 5.04 | 17; 12.3 (7.8–18.9); 6.85 |
| Ng et al., Mar 2020 | Singapore | 100 | 0; 0.5 (0–7.4); 1.47 | NA |
| Spiteri et al., Mar 2020 | Europe | 38 | 1; 2.6 (0.4–16.5); 2.36 | 1; 2.6 (0.4–16.5); 2.53 |
| COVID-19 National Incident Room Surveillance Team, Mar 2020 | Australia | 71 | 2; 2.8 (0.7–10.6); 3.47 | NA |
| Xu et al., Feb 2020 | China | 62 | 0; 0.8 (0–11.5); 1.46 | 1; 1.6 (0.2–10.6); 2.55 |
| Bajema et al., Feb 2020 | USA | 11 | 1; 9.1 (1.3–43.9)a; 2.26 | NA |
| Chen et al., Jan 2020 | China | 99 | 11; 11.1 (6.3–19); 5.57 | NA |
| Yang et al., Feb 2020 | China | 52 | 32; 61.5 (47.8–73.7)b; 5.75 | 37; 71.2 (57.5–81.8); 6.54 |
| Wang et al., Mar 2020 | China | 69 | 5; 7.2 (3–16.3); 4.78 | NA |
| Mo et al., Mar 2020 | China | 155 | NA | 36; 23.2 (17.2–30.5); 7.25 |
| Arentz et al., Mar 2020 | USA | 21 | 11; 52.4 (31.8–72.1)c; 4.93 | 15; 71.4 (49.2–86.6); 5.29 |
| Wu et al., Mar 2020 | China | 201 | 44; 21.9 (16.7–28.1); 6.24 | 67; 33.3 (27.2–40.1); 7.44 |
| Zhou et al., Mar 2020 | China | 191 | 54; 28.3 (22.3–35.1); 6.28 | 58; 30.4 (24.3–37.3); 7.41 |
| Wang et al., Mar 2020 | China | 339 | 65; 19.2 (15.3–23.7); 6.35 | 80; 23.6 (19.4–28.4); 7.53 |
| Guo et al., Mar 2020 | China | 187 | 43; 23 (17.5–29.6); 6.23 | 45; 24.1 (18.5–30.7); 7.35 |
| Richardson et al., Apr 2020 | USA | 5700 | 553; 9.7 (9–10.5); 6.53 | 1151; 20.2 (19.2–21.3); 7.76 |
| Goyal et al., Apr 2020 | USA | 393 | 40;10.2 (7.6–13.6); 6.26 | 130; 33.1 (28.6–37.9); 7.6 |
| Ruan et al., Mar 2020 | China | 150 | 68; 45.3 (37.6–53.4)d; 6.27 | 79; 52.7 (44.7–60.5); 7.38 |
| Qian et al., Mar 2020 | China | 91 | 0;0.5 (0–8.1); 1.47 | NA |
| Paranjpe et al., Apr 2020 | USA | 2199 | 310; 14.1 (12.7–15.6); 6.51 | NA |
| Lauer et al., Mar 2020 | China | 181 | NA | NA |
| Chang et al., Feb 2020 | China | 13 | NA | NA |
| Kim et al., Feb 2020 | South Korea | 28 | NA | NA |
| Qin et al., Mar 2020 | China | 452 | NA | NA |
| Zhang et al., Feb 2020 | China | 140 | NA | NA |
| Total | 12,258 | 1267; 13 (9.3–18); 100 | 1789; 23.3 (17.1–30.9); 100 |
Total number (n =) of patients included for COVID-19 epidemiology evaluation 12,258, mortality prevalence 11,252, and for mechanical ventilation utilization 8804
* Statistically significant at p < 0.001 except (a) p = 0.028, (b) p = 0.099, (c) p = 0.827, and (d) p = 0.254
#Weight (%) = relative weight (random)